CervoMed

About CervoMed

CervoMed Inc. is a clinical-stage biopharmaceutical company with a strategic focus on developing therapeutics for age-related neurodegenerative disorders. The company's operations are centered on its lead drug candidate, neflamapimod, an orally administered, brain-penetrating small molecule designed to inhibit the p38 mitogen-activated protein kinase (MAPK) alpha. This mechanism is believed to address synaptic dysfunction, a reversible aspect of the neurodegeneration that underlies conditions such as Dementia with Lewy Bodies (DLB) and Alzheimer's disease.

The company was originally founded as EIP Pharma in 2014 by seasoned pharmaceutical R&D executives John Alam, MD, and Sylvie Grégoire, PharmD. Dr. Alam, who currently serves as CEO, brings over three decades of experience in translational medicine, having held senior roles at Sanofi, Vertex Pharmaceuticals, and Biogen, where he was instrumental in developing innovative medicines for diseases like multiple sclerosis, HIV, and Hepatitis C. In August 2023, EIP Pharma completed a reverse merger with Diffusion Pharmaceuticals, subsequently rebranding to CervoMed and listing on NASDAQ under the ticker CRVO.

CervoMed's primary business model is rooted in the clinical development and eventual commercialization of neflamapimod. Its revenue stream is currently supported by grants, including a significant award from the National Institutes of Health's National Institute on Aging to fund its clinical trials. The company targets a significant unmet medical need, as DLB is the third most common degenerative brain disease with no currently approved treatments by the FDA or EMA. CervoMed's main clients are patients suffering from these debilitating neurodegenerative diseases.

Neflamapimod is under evaluation in multiple clinical trials. The most prominent is the RewinD-LB study, a Phase 2b trial for patients with DLB. Recent positive results from the extension phase of this trial showed that neflamapimod could slow clinical progression, with these findings linked to higher plasma drug concentrations from a new batch of capsules. Based on these encouraging results, CervoMed plans to engage with regulatory authorities to initiate a Phase 3 trial by mid-2026. The company is also expanding the potential applications of neflamapimod by launching separate Phase 2a trials for patients with primary progressive aphasia (a subtype of frontotemporal dementia) and for those recovering from ischemic stroke, broadening the drug's therapeutic potential.